相关实验视频

Updated: Jun 27, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

将STING放回BH3-模拟药物中,用于TP53-突变血液癌症

Sarah T Diepstraten¹, Yin Yuan², John E La Marca³

¹Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia.

|April 26, 2024

概括

治疗TP53突变血液癌症是很困难的. 激活cGAS/STING通路与STING激动剂以及BH3-模拟药物一起,通过升级BH3-仅蛋白质来杀死这些癌细胞的新方法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

发生TP53突变的血液癌症带来了重大的临床挑战.
BH3-模仿药物通过抑制BCL-2诱导癌细胞亡,但它们的疗效在TP53-缺乏癌症中是有限的.
功能性p53增强BH3-模仿药物的疗效的确切机制尚不清楚.

研究的目的:

阐明p53在BH3-模仿药物的疗效中介作用.
为了确定TP53-突变血液癌症的替代治疗策略.
研究cGAS/STING通路作为治疗点的潜力.

主要方法:

在BH3-模拟治疗后研究了p53激活.
分析了p53依赖的前循环在亡中的作用.
在临床前模型中与BH3-模拟药物结合使用STING激动剂.

主要成果:

在线粒体外膜透后,p53被激活,诱导仅BH3的蛋白质并增强亡.
缺乏TP53的淋巴瘤缺乏这种亲细胞亡的反循环,导致治疗抵抗.
通过直接激活cGAS/STING通路,通过BH3-only蛋白上调促进p53独立的亡.
用STING激动剂和BH3-模拟剂的组合疗法证明了对各种TP53-突变血液癌细胞的强有力的杀死.

结论:

一个新的p53-依赖的前循环放大了BH3-模拟诱导的亡.
该cGAS/STING途径提供了一个可行的治疗策略,以克服p53缺陷在血液癌症.
与STING激动剂和BH3-模拟剂的联合治疗显示出治疗TP53-突变血液癌症的前景.

关键词:

仿制BH3的药物仿制药物刺痛是一种刺痛.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.灭症 (apoptosis) 是一种死亡的过程.血液癌症血液癌症血液癌症淋巴瘤淋巴瘤是什么在 p53 里,p53 是一个 p53 的代码.

更多相关视频

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...